Log in
(Ad)
One of the best ways to double, if not triple your investment in 2020 will be found in tech stocks. Especially those involved with the 5G rollout, where we're still finding undervalued opportunities. In our latest special report, we detail these and other hot tech stocks that should be part of your portfolio right now.

NASDAQ:AGEN - Agenus Stock Price, Forecast & News

$4.00
+0.10 (+2.56 %)
(As of 01/23/2020 07:41 AM ET)
Add
Compare
Today's Range
$3.88
Now: $4.01▼
$4.03
50-Day Range
$3.50
MA: $3.89▼
$4.19
52-Week Range
$2.13
Now: $4.01▼
$4.57
Volume1.57 million shs
Average Volume892,106 shs
Market Capitalization$550.13 million
P/E RatioN/A
Dividend YieldN/A
Beta2.09
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AGEN
Previous Symbol
CUSIP00847G70
CIK1098972
Webhttp://agenusbio.com/
Phone781-674-4400

Debt

Debt-to-Equity RatioN/A
Current Ratio0.81
Quick Ratio0.81

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$36.78 million
Price / Sales14.96
Cash FlowN/A
Price / Cash FlowN/A
Book Value($1.45) per share
Price / Book-2.76

Profitability

EPS (Most Recent Fiscal Year)($1.44)
Net Income$-159,690,000.00
Net Margins-107.15%
Return on EquityN/A
Return on Assets-67.84%

Miscellaneous

Employees294
Outstanding Shares137,360,000
Market Cap$550.13 million
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable

Receive AGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:AGEN Rates by TradingView

(Ad)

Investors looking for the best way to potentially double their money in 2020 -- regardless of whether the overall markets are up or down -- should look no further than these 3 unique stocks.

This Special Report reveals the names of these stocks and provides everything you need to invest right away.

Agenus (NASDAQ:AGEN) Frequently Asked Questions

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

How were Agenus' earnings last quarter?

Agenus Inc (NASDAQ:AGEN) announced its earnings results on Monday, November, 4th. The biotechnology company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.05. The biotechnology company had revenue of $19.94 million for the quarter, compared to analyst estimates of $15.60 million. View Agenus' Earnings History.

When is Agenus' next earnings date?

Agenus is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Agenus.

What price target have analysts set for AGEN?

1 equities research analysts have issued twelve-month price targets for Agenus' shares. Their forecasts range from $6.00 to $6.00. On average, they anticipate Agenus' stock price to reach $6.00 in the next year. This suggests a possible upside of 49.8% from the stock's current price. View Analyst Price Targets for Agenus.

What is the consensus analysts' recommendation for Agenus?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agenus.

Has Agenus been receiving favorable news coverage?

Media stories about AGEN stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Agenus earned a news impact score of -1.3 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Agenus.

Are investors shorting Agenus?

Agenus saw a increase in short interest in December. As of December 31st, there was short interest totalling 11,730,000 shares, an increase of 15.3% from the December 15th total of 10,170,000 shares. Based on an average daily trading volume, of 1,230,000 shares, the days-to-cover ratio is currently 9.5 days. Currently, 11.2% of the shares of the company are short sold. View Agenus' Current Options Chain.

Who are some of Agenus' key competitors?

What other stocks do shareholders of Agenus own?

Who are Agenus' key executives?

Agenus' management team includes the folowing people:
  • Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 66)
  • Dr. Jennifer Buell, Chief Operating Officer
  • Dr. Alexander R. Duncan, CTO & Head of Research (Age 57)
  • Dr. Christian Cortis, Chief Strategy Officer & Head of Fin. (Age 51)
  • Ms. Christine M. Klaskin, Principal Accounting Officer & VP of Fin. (Age 53)

Who are Agenus' major shareholders?

Agenus' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Zurcher Kantonalbank Zurich Cantonalbank (0.01%). View Institutional Ownership Trends for Agenus.

Which institutional investors are selling Agenus stock?

AGEN stock was sold by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Agenus.

How do I buy shares of Agenus?

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $4.01.

How big of a company is Agenus?

Agenus has a market capitalization of $550.13 million and generates $36.78 million in revenue each year. The biotechnology company earns $-159,690,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Agenus employs 294 workers across the globe.View Additional Information About Agenus.

What is Agenus' official website?

The official website for Agenus is http://agenusbio.com/.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]


MarketBeat Community Rating for Agenus (NASDAQ AGEN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  411 (Vote Outperform)
Underperform Votes:  317 (Vote Underperform)
Total Votes:  728
MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe AGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Featured Article: Using other technical indicators with support levels
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel